NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ACIU

AC Immune SA

Apr 17 • 04:00PM ET

1.48

Dollar change -0.02
Percentage change -1.33	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: BIIB LLY SNY PRTA QURE SAVA ABEO ANVS AXSM INMB

| Held by: IBB DFAT DFAC DFAS IBBQ BIB DFSU BMED DXUV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	37.89%	Shs Outstand	100.41M	Perf Week	0.00%
Market Cap	146.44M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	0.00%	Shs Float	61.45M	Perf Month	-33.33%
Income	-57.25M	PEG	-	EPS next Q	-0.23	Inst Own	27.81%	Short Float	2.34%	Perf Quarter	-43.94%
Sales	31.47M	P/S	4.65	EPS this Y	-2.13%	Inst Trans	-8.78%	Short Ratio	7.49	Perf Half Y	-53.75%
Book/sh	1.23	P/B	1.20	EPS next Y	-28.31%	ROA	-24.26%	Short Interest	1.44M	Perf Year	-39.59%
Cash/sh	1.85	P/C	0.80	EPS next 5Y	-	ROE	-36.38%	52W Range	1.43 - 4.98	Perf YTD	-45.19%
Dividend Est.	-	P/FCF	1.97	EPS past 5Y	-	ROI	-44.47%	52W High	-70.27%	Beta	1.65
Dividend TTM	-	Quick Ratio	1.71	Sales past 5Y	40.56%	Gross Margin	-	52W Low	3.50%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.71	EPS Y/Y TTM	18.78%	Oper. Margin	-187.86%	RSI (14)	24.24	Volatility	4.84% 6.76%
Employees	172	Debt/Eq	0.05	Sales Y/Y TTM	88.63%	Profit Margin	-181.91%	Recom	1.00	Target Price	10.63
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-211.76%	Payout	-	Rel Volume	0.33	Prev Close	1.50
Sales Surprise	78.23%	EPS Surprise	9.58%	Sales Q/Q	-92.23%	Earnings	Mar 13 BMO	Avg Volume	191.89K	Price	1.48
SMA20	-15.00%	SMA50	-32.20%	SMA200	-49.95%	Trades		Volume	63,733	Change	-1.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-24	Initiated	BTIG Research	Buy	$8
Feb-01-19	Downgrade	UBS	Buy → Neutral
Jan-04-19	Initiated	UBS	Buy
Apr-05-18	Initiated	H.C. Wainwright	Buy	$18
Mar-23-18	Downgrade	Credit Suisse	Outperform → Neutral
Oct-18-16	Initiated	Leerink Partners	Outperform
Oct-18-16	Initiated	Jefferies	Buy	$25
Oct-18-16	Initiated	Credit Suisse	Outperform	$18

Apr-03-25 09:46AM	AC Immune reports interim outcomes from trial of Parkinsons therapy (Clinical Trials Arena) -5.85%
Apr-02-25 06:00AM	AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire)
Mar-25-25 07:00AM	AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD 2025 (GlobeNewswire) -6.60%
Mar-24-25 03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
Mar-13-25 07:00AM	AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
12:00PM	Loading…
Mar-05-25 12:00PM	AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +6.38%
Mar-04-25 07:00AM	AC Immune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-25 09:35AM	Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) (Zacks) +10.74%
Dec-11-24 07:26AM	AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 (TipRanks)
Dec-10-24 07:00AM	AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome (GlobeNewswire)
Nov-15-24 12:33PM	AC Immunes stock jumps after Parkinsons therapy shows signs of benefit (Pharmaceutical Technology) -10.14%
07:30AM	AC Immune reports interim results from Phase 2 trial of ACI-7104.056 (TipRanks)
Nov-14-24 07:00AM	AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire) +13.42%
Nov-13-24 07:00AM	AC Immune to Present at the Jefferies 2024 London Healthcare Conference (GlobeNewswire)
Nov-05-24 07:30AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance) +10.20%
07:00AM	Loading…
07:00AM	AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-23-24 09:12AM	What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings (GuruFocus.com)
Sep-17-24 07:00AM	AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease (GlobeNewswire) +5.81%
Aug-29-24 07:13AM	FDA grants fast track designation to Life Molecular Imagings tau PET diagnostic (Medical Device Network)
Aug-28-24 09:00AM	AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions (GlobeNewswire)
Aug-06-24 09:25AM	AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:23AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-31-24 08:30AM	AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire)
Jul-25-24 12:53PM	AC Immune wins FDA fast track for Alzheimers vaccine (Pharmaceutical Technology) +10.76%
07:00AM	AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Jul-16-24 07:00AM	AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire) +5.15%
May-28-24 07:00AM	AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 (GlobeNewswire) +9.32%
May-13-24 03:58PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires) +42.86%
03:37PM	Sector Update: Health Care (MT Newswires)
02:53PM	Loading…
02:53PM	ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 (InvestorPlace)
02:41PM	Top Midday Gainers (MT Newswires)
11:22AM	Takeda shells out $100m to license AC Immunes Phase II Alzheimers therapy (Pharmaceutical Technology)
08:13AM	Why Is AC Immune (ACIU) Stock Up 45% Today? (InvestorPlace)
08:02AM	Takeda nabs option to license Alzheimers immunotherapies from AC Immune (BioPharma Dive)
08:00AM	Top Premarket Gainers (MT Newswires)
07:26AM	Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate (MT Newswires)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:12AM	AC Immune: Q1 Earnings Snapshot (Associated Press Finance)
06:05AM	AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
06:00AM	AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease (Business Wire)
05:52AM	Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears (FierceBiotech.com)
Mar-14-24 10:52PM	ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.00% +5.11%
07:00AM	AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-24 07:00AM	AC Immune Announces Upcoming Presentations at AD/PD 2024 (GlobeNewswire)
Feb-21-24 11:16AM	5 Little-Known Penny Stocks With Massive Upside Potential (Insider Monkey)
Jan-30-24 09:35AM	Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround (Zacks)
Jan-22-24 08:48AM	Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech (FierceBiotech.com)
07:00AM	AC Immune to Regain Global Rights to Crenezumab and Semorinemab (GlobeNewswire)
Jan-18-24 12:00PM	AC Immune (ACIU) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-03-24 12:00PM	AC Immune (ACIU) Upgraded to Buy: Here's Why (Zacks)
08:10AM	AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases (GlobeNewswire)
Dec-15-23 07:56AM	AC Immune Announces Pricing of Underwritten Offering of Common Shares (GlobeNewswire) +5.66%
07:22AM	AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial (GlobeNewswire)
Dec-05-23 05:59AM	Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now? (Zacks)
Dec-01-23 07:00AM	AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO (GlobeNewswire)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) +7.02%
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
Nov-07-23 07:00AM	AC Immune to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Nov-03-23 08:37AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023 (GlobeNewswire)
Oct-27-23 07:00AM	AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic (GlobeNewswire) -6.55%
Oct-24-23 09:40AM	Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.66%
Oct-23-23 10:00AM	Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline (Zacks) +7.72%
Oct-20-23 10:00AM	AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks) -11.19%
Oct-18-23 08:26AM	NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Oct-17-23 07:00AM	AC Immune Announces Upcoming Presentations at the 16th CTAD Conference (GlobeNewswire)
Oct-05-23 07:00AM	AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 (GlobeNewswire)
Sep-05-23 01:09PM	AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why (Zacks)
08:48AM	Are Options Traders Betting on a Big Move in AC Immune (ACIU) Stock? (Zacks)
07:00AM	AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 (GlobeNewswire)
Aug-04-23 08:15AM	AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:14AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-28-23 07:00AM	AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-26-23 07:00AM	AC Immune SA Appoints New Chief Medical Officer (GlobeNewswire)
Jul-03-23 07:00AM	AC Immune Showcasing Precision Medicine Programs at AAIC 2023 (GlobeNewswire)
Jun-30-23 03:13PM	Why Shares of AC Immune Jumped This Week (Motley Fool)
Jun-27-23 07:00AM	AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimers Disease (GlobeNewswire) +71.72%
Jun-23-23 04:30PM	AC Immune Holds Annual General Meeting of Shareholders (GlobeNewswire)
Jun-16-23 10:45AM	Private equity firms among AC Immune SA's (NASDAQ:ACIU) largest stockholders and were hit after last week's 12% price drop (Simply Wall St.)
May-04-23 09:02AM	Here's Why We're Watching AC Immune's (NASDAQ:ACIU) Cash Burn Situation (Simply Wall St.) +11.35%
Apr-28-23 07:14AM	AC Immune: Q1 Earnings Snapshot (AP Finance)
07:00AM	AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace) +6.25% -7.84%
Apr-07-23 08:29AM	AC Immune (NASDAQ:ACIU) shareholders have endured a 76% loss from investing in the stock five years ago (Simply Wall St.)
Apr-05-23 07:00AM	AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimers Disease (GlobeNewswire)
Mar-20-23 08:00AM	AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline (GlobeNewswire)
Mar-16-23 07:00AM	AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 07:00AM	AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 (GlobeNewswire)
Feb-07-23 07:00AM	AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 (GlobeNewswire)
Feb-02-23 08:15AM	AC Immune to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 09:57AM	Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance (Zacks)
Jan-26-23 07:00AM	AC Immunes ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimers Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial (GlobeNewswire)
Jan-18-23 07:00AM	AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimers Disease (GlobeNewswire)
Jan-07-23 08:45AM	AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29% (Simply Wall St.)
Nov-30-22 07:00AM	AC Immunes Alzheimers Disease Vaccine-candidate ACI-35.030 Selected for Further Development (GlobeNewswire)
Nov-25-22 07:17AM	Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely? (Simply Wall St.) +7.39%
Nov-23-22 07:30AM	AC Immune to Present Progress of Alzheimers Disease Programs targeting Abeta and Tau at the 15th CTAD Conference (GlobeNewswire)

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANDREA M. A PFEIFER	Officer	Sep 27 '24	Proposed Sale	3.70	40,000	148,000		Sep 27 04:26 PM
ANDREA M. A PFEIFER	Officer	Sep 18 '24	Proposed Sale	3.46	20,000	69,200		Sep 18 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACIU

AC Immune SA

Upgrade your FINVIZ experience